Market
Outcome of amycretin Phase 2 trials by end of 2025?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial halted • 25%
Novo Nordisk press releases and clinical trial results publications
Story
Novo Nordisk Shares Surge Over 12% After Amycretin Shows Up to 22% Weight Loss in Early Trial
Jan 24, 2025, 12:00 PM
Novo Nordisk announced positive results from an early-stage Phase 1b/2a trial of its new obesity drug, amycretin. The trial involved 125 participants with overweight or obesity, who achieved up to 22% weight loss over 36 weeks when treated with amycretin. The drug is a novel GLP-1 and amylin receptor agonist designed for once-weekly subcutaneous injection. Following the announcement, Novo Nordisk shares surged more than 12%, their largest increase in a month.
View original story
Similar markets
Worsening condition • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Moderate improvement • 25%
Worse outcomes • 25%
No improvement • 25%
Significant improvement • 25%
Successful with significant results • 25%
Trial not initiated • 25%
Unsuccessful • 25%
Successful with moderate results • 25%
Positive efficacy and safety results • 25%
Negative efficacy and safety concerns • 25%
Negative efficacy, but good safety • 25%
Positive efficacy, but safety concerns • 25%
Successful trial • 33%
Unsuccessful trial • 33%
Inconclusive results • 34%
15% to 20% • 25%
Less than 15% • 25%
20% to 25% • 25%
More than 25% • 25%
Negative results • 25%
Inconclusive results • 25%
Trial extended • 25%
Positive results • 25%